Project Grant R01DA058666
Award Date
7/15/24
Completion Date
4/30/29
Dollars Obligated
$2.2M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Jackson, MS 39216, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $1,243,350.00 to the University of Nebraska Medical Center (UNMC) to conduct research on the mechanisms underlying sleep disturbances during opioid withdrawal. The primary objectives are to: Determine if and how chronic morphine administration disrupts the neuronal activity and properties of wake-active noradrenergic neurons in the...
This Project Grant award of $458,452 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to identify genes and molecular mechanisms that affect psychostimulant-induced sleep irregularities as well as sleep deprivation-caused changes in experience-dependent amphetamine preference in the vinegar fly, Drosophila melanogaster. The key objectives are to: 1) Determine mechanisms of stimulant-induced sleep changes, 2)...
This Project Grant award, valued at $1,118,601.00, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award, effective July 15, 2024 and running through May 31, 2029, supports research at Rutgers University on the role of orexin (hypocretin) signaling in the ventral tegmental area as a common mechanism underlying both sleep disturbances and drug craving during cocaine abstinence. The key objectives of this research...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $1,432,293 to the University of Massachusetts Medical School to investigate the role of the circadian transcription factor NPAS2 and dopamine D3 receptor signaling in opioid craving and relapse behaviors. The research aims to elucidate the molecular mechanisms linking sleep/circadian rhythms and opioid addiction, with a focus on the medial shell of...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) is intended to study the impact of preadolescent psychostimulant exposure, such as methylphenidate (MPH) for attention-deficit/hyperactivity disorder (ADHD), on sleep neurophysiology and circadian rhythms in a rodent model. The $181,234 award, granted on August 23, 2024, will fund two key studies over the project period ending June 30, 2028. The...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will advance the development of troriluzole as a treatment for methamphetamine use disorder (MUD), including co-occurring MUD and opioid use disorder (OUD). The $634,048 award will fund a human laboratory study to evaluate the reinforcing effects of methamphetamine and the ability of troriluzole to reduce these effects in individuals with MUD...
The National Institute on Drug Abuse (NIDA), through its Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1,523,422 Project Grant to Virginia Commonwealth University (VCU) with a start date of September 30, 2024 and an ultimate completion date of July 31, 2029. The primary objective of this grant is to investigate the role of the orexin system at the intersection of opioid use disorder (OUD) and insomnia. Specifically, the study will utilize lemborexant, an FDA-approved dual...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports a study titled "Methamphetamine Activation of Inflammasome and Altered Immunity in HIV (MAIA)". The $1,481,760 award, spanning from September 30, 2024 to July 31, 2029, will be conducted by Emory University to investigate how methamphetamine exposure leads to inflammasome activation and immune dysfunction in people living with HIV on...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $395,995 to Oregon Health & Science University (OHSU) to conduct a longitudinal study examining the reciprocal relationships between cannabis use, sleep, and the hypothalamic-pituitary-adrenal (HPA) axis. The 5-year study will enroll 60 participants, including healthy controls, individuals with moderate cannabis use, and those with cannabis...
This $314,225 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to explore the unique neurobehavioral profile of sequential opioid-stimulant polysubstance use disorders. The study aims to: 1) Define the behavioral patterns of dual opioid-methamphetamine use disorders in a rodent model, and 2) Map neural activation patterns in the cortico-basal ganglia-thalamic circuit in response to opioid...